Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group
Cristiana Sessa(Institute of Oncology Research), Jan B. Vermorken(University of Antwerp), Aarón Sulkes, R Eppelbaum, W ten Bokkel Huinink(European Organisation for Research and Treatment of Cancer), Steinar Aamdal(Humboldt-Universität zu Berlin), Ingmar Wolff(Universitätsmedizin Greifswald), J. Wanders(Eisai (United Kingdom)), H. Franklin(Oregon Health & Science University), John F. Smyth(Western General Hospital)
Cited by 37
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k